Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;22(7):1233-1247.
doi: 10.2174/1570159X22666231128101725.

Immunomodulatory Effects of Clozapine: More Than Just a Side Effect in Schizophrenia

Andrea Amerio  1   2 , Luca Magnani  1 , Gabriele Arduino  1 , Fabio Fesce  1 , Renato de Filippis  3 , Alberto Parise  4 , Alessandra Costanza  5   6 , Khoa D Nguyen  7   8 , Daniele Saverino  2   9 , Domenico De Berardis  10 , Andrea Aguglia  1   2 , Andrea Escelsior  1   2 , Gianluca Serafini  1   2 , Pasquale De Fazio  3 , Mario Amore  1   2
Affiliations
Review

Immunomodulatory Effects of Clozapine: More Than Just a Side Effect in Schizophrenia

Andrea Amerio et al. Curr Neuropharmacol. 2024.

Abstract

Recent evidence suggests a possible relationship between the immune system and schizophrenia spectrum disorders (SSDs), as neuroinflammation appears to play a role in major psychiatric conditions. Neuroinflammation is as a broad concept representing a physiological protective response to infection or injury, but in some cases, especially if chronic, it may represent an expression of maladaptive processes, potentially driving to clinical dysfunction and neurodegeneration. Several studies are concurrently highlighting the importance of microglia, the resident immune cells of the central nervous system, in a huge number of neurodegenerative diseases, including multiple sclerosis, Alzheimer's and Parkinson's diseases, as well as SSDs. A more fundamental phenomenon of maladaptive coupling of microglia may contribute to the genesis of dysfunctional brain inflammation involved in SSDs, from the onset of their neurophenomenological evolution. Clozapine and other antipsychotic drugs seem to express a provable immunomodulant effect and a more specific action on microglia, while neuroactive steroids and nonsteroidal anti-inflammatory drugs may reduce some SSDs symptoms in add-on therapy. Given these theoretical premises, this article aims to summarize and interpret the available scientific evidence about psychotropic and anti-inflammatory drugs that could express an immunomodulant activity on microglia.

Keywords: Clozapine; SSDs.; immunomodulation; microglia; neuroinflammation; schizophrenia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest, financial or otherwise.

References

    1. Owen M.J., O’Donovan M.C., Thapar A., Craddock N. Neurodevelopmental hypothesis of Schizophrenia. Br. J. Psychiatry. 2011;198(3):173–175. doi: 10.1192/bjp.bp.110.084384. - DOI - PMC - PubMed
    1. Mullin A.P., Gokhale A., Moreno-De-Luca A., Sanyal S., Waddington J.L., Faundez V. Neurodevelopmental disorders: Mechanisms and boundary definitions from genomes, interactomes and proteomes. Transl. Psychiatry. 2013;3(12):e329. doi: 10.1038/tp.2013.108. - DOI - PMC - PubMed
    1. Belsky J., Pluess M. Beyond diathesis stress: Differential susceptibility to environmental influences. Psychol. Bull. 2009;135(6):885–908. doi: 10.1037/a0017376. - DOI - PubMed
    1. Ripke S., Neale B.M., Corvin A., Walters J.T.R., Farh K.H., Holmans P.A. Biological insights from 108 Schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–427. doi: 10.1038/nature13595. - DOI - PMC - PubMed
    1. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., Werge T., Pietiläinen O.P.H., Mors O., Mortensen P.B., Sigurdsson E., Gustafsson O., Nyegaard M., Tuulio-Henriksson A., Ingason A., Hansen T., Suvisaari J., Lonnqvist J., Paunio T., Børglum A.D., Hartmann A., Fink-Jensen A., Nordentoft M., Hougaard D., Norgaard-Pedersen B., Böttcher Y., Olesen J., Breuer R., Möller H.J., Giegling I., Rasmussen H.B., Timm S., Mattheisen M., Bitter I., Réthelyi J.M., Magnusdottir B.B., Sigmundsson T., Olason P., Masson G., Gulcher J.R., Haraldsson M., Fossdal R., Thorgeirsson T.E., Thorsteinsdottir U., Ruggeri M., Tosato S., Franke B., Strengman E., Kiemeney L.A., Melle I., Djurovic S., Abramova L., Kaleda V., Sanjuan J., de Frutos R., Bramon E., Vassos E., Fraser G., Ettinger U., Picchioni M., Walker N., Toulopoulou T., Need A.C., Ge D., Yoon J., Shianna K.V., Freimer N.B., Cantor R.M., Murray R., Kong A., Golimbet V., Carracedo A., Arango C., Costas J., Jönsson E.G., Terenius L., Agartz I., Petursson H., Nöthen M.M., Rietschel M., Matthews P.M., Muglia P., Peltonen L., St Clair D., Goldstein D.B., Stefansson K., Collier D.A. Common variants conferring risk of schizophrenia. Nature. 2009;460(7256):744–747. doi: 10.1038/nature08186. - DOI - PMC - PubMed

MeSH terms